Congenital toxoplasmosis treatment

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 2, 2011, Pages 193-198

  Serranti, D ^a   Buonsenso, D ^a   Valentini, Piero ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Congenital toxoplasmosis; Pyrimethamine; Randomized controlled trial; Spiramycine; Sulfadiazine

Indexed keywords

ATOVAQUONE; AZITHROMYCIN; FOLINIC ACID; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PYRIMETHAMINE; SPIRAMYCIN; SULFADIAZINE;

AGGLUTINATION TEST; ARTICLE; CLINICAL TRIAL; CONGENITAL TOXOPLASMOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LATEX AGGLUTINATION TEST; POLYMERASE CHAIN REACTION; POSTNATAL CARE; PRENATAL CARE; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASOUND;

FEMALE; GUIDELINES AS TOPIC; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, PARASITIC; TOXOPLASMA; TOXOPLASMOSIS, CONGENITAL;

EID: 79953242768     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. MCCARTHY M. Of cats and women. Br Med J (Clin Res Ed) 1983; 287(6390): 445-446.
2. COOK AJ, GILBERT RE, BUFFOLANO W, ZUFFEREY J, PETERSEN E, JENUM PA, FOULON W, SEMPRINI AE, DUNN DT. Sources of toxoplasma infection in pregnant women: European multicentre case-control study. Br Med J 2000; 321(7254): 142-147.
3. REMINGTON J, MCLEOD R, THULLIEZ P, DESMONTS G. TOXOPLASMOSIS. IN: REMINGTON JS, KLEIN JO, EDS. Infectious diseases of the fetus and newborn infant. Philadelphia; WB Saunders; 2001.
4. KOPPE JG, LOEWE-SIEGER DH, DE ROEVER-BONNET. Results of 20-years follow-up of congenital toxoplasmosis. Lancet 1986; 1: 254-260.
5. ANCELLE T, GOULET V, TIRARD-FLEURY V, BARIL L, DU MAZAUBRUN C, THULLIEZ PH. La toxoplasmose chez la femme enceinte en France en 1995. Bull Epidemiol Hebdomadaire Direction Generale Santé 1996; 51: 227-228.
6. DESMONTS G, COUVREUR J, ALISON F, BAUDELOT. J, GERBEAUX J, LELONG M. Étude epidemiologique sur la toxoplasmose: l'influence de la cuisson des viandes de boucherie sur la frequence de l'infection humaine. Rev Franç Étud Cliniq Biol 1965; 10: 952-958.
7. GOULET V, LE STRAT Y, DESENCLOS JC. Toxoplasmosis among pregnant women in France: risk factors and change of prevalence between 1995 and 2003. Rev Epidemiol Santé Publique 2009; 57: 241-248.
8. BESSIÈRES MH, BERREBI A, CASSAING S, FILLAUX J, CAMBUS JP, BERRY A, ASSOULINE C, AYOUBI JM, MAGNAVAL JF. Diagnosis of congenital toxoplasmosis: prenatal and neonatal evaluation of methods used in Toulouse University Hospital and incidence of congenital toxoplasmosis. Mem Inst Oswaldo Cruz 2009; 104: 389-392.
9. CARTER AO, FRANK JW. Congenital toxoplasmosis: epidemiological features and control. Can Med Assoc J 1986; 135: 618-623.
10. LEBECH M, JOYNSON DH, SEITZ HM, THULLIEZ P, GILBERT RE, DUTTON GN, OVLISEN B, PETERSEN E. Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis. Eur J Clin Microbiol Infect Dis 1996; 15: 799-805.
11. ROMAND S, WALLON M, FRANCK J, THULLIEZ P, PEYRON F, DUMON H. Prenatal diagnosis using polymerase chain reaction on amniotic fluid for congenital toxoplasmosis. Obstet Gynecol 2001; 97: 296-300.
12. MONTOYA JG, REMINGTON JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis 2008; 47: 554-566.
13. COUVREUR J, DESMONTS G, THULLIEZ P. Prophylaxis of congenital toxoplasmosis: effects of spiramycin on placental infection. J Antimicrob Chemother 1988; 22: 193-200.
14. COUVREUR J, THULLIEZ P, DAFFOS F, AUFRANT C, BOMPARD Y, GESOUIERE A, DESMONTS G. In utero treatment of toxoplasmic fetopathy with the combination pyrimethamine-sulfadiazine. Fetal Diagn Ther 1993; 8: 45-50.
15. HOHLFELD P, DAFFOS F, THULLIEZ P, AUFRANT C, COUVREUR J, MACALEESE J, DESCOMBEY D, FORESTIER F. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989; 115: 765-769.
16. SYROCOT (SYSTEMATIC REVIEW ON CONGENITAL TOXOPLASMOSIS) STUDY GROUP, THIÉBAUT R, LEPROUST S, CHÊNE G, GILBERT R. Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet 2007; 369: 115-122.
17. PETERSEN E. Toxoplasmosis. Semin Fetal Neonatal Med 2007; 12: 214-223.
18. DEROUIN F. Anti-toxoplasmosis drugs. Curr Opin Investig Drugs 2001; 2: 1368-1374.
19. COSTA IN, ANGELONI MB, SANTANA LA, BARBOSA BF, SILVA MC, RODRIGUES AA, ROSTKOWSA C, MAGALHÃES PM, PENA JD, SILVA DA, MINEO JR, FERRO EA. Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 2009; 30: 884-890.
20. MARTINS-DUARTE ES, JONES SM, GILBERT IH, ATELLA GC, DE SOUZA W, VOMMARO RC. Thiolactomycin analogues as potential anti-Toxoplasma gondii agents. Parasitol Int 2009; 58: 411-415.
21. VALENTINI P, ANNUNZIATA ML, ANGELONE DF, MASINI L, DE SANTIS M, TESTA A, GRILLO RL, SPEZIALE D, RANNO O. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur J Clin Microbiol Infect Dis 2009; 28: 297-300.
22. REMINGTON JS, MCLEOD R, THULLIEZ P, DESMONTS G. Toxoplasmosis. In: J Remington, G Klein, C Wilson, C Baker (eds.), Infectious diseases of the fetus and newborn infant, 6th ed., WB Saunders; Philadelphia; 2006.
23. MCLEOD R, MACK D, FOSS R, BOYER K, WITHERS S, LEVIN S, HUBBELL J. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Antimicrob Agents Chemother 1992; 36: 1040-1048.
24. MCLEOD R, BOYER K, KARRISON T, KASZA K, SWISHER C, ROIZEN N, JALBRZIKOWSKI J, REMINGTON J, HEYDEMANN P, NOBLE AG, METS M, HOLFELS E, WITHERS S, LATKANY P, MEIER P; TOXOPLASMOSIS STUDY GROUP. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006; 42: 1383-1394.
25. PHAN L, KASZA K, JALBRZIKOWSKI J, NOBLE AG, LATKANY P, KUO A, MIELER W, MEYERS S, RABIAH P, BOYER K, SWISHER C, METS M, ROIZEN N, CEZAR S, REMINGTON J, MEIER P, MCLEOD R; TOXOPLASMOSIS STUDY GROUP. Longitudinal study of new eye lesions in treated congenital toxoplasmosis. Ophthalmology 2008; 115: 553-559.
26. HUSKINSON-MARK J, ARAUJO FG, REMINGTON JS. Evaluation of the effect of drugs on the cyst form of Toxoplasma gondii. J Infect Dis 1991; 164: 170-171.
27. ARAUJO FG, HUSKINSON J, REMINGTON JS. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob Agents Chemother 1991; 35: 293-299.
28. DJURKOVIC-DJAKOVIC O, MILENKOVIC V, NIKOLIC A, BOBIC B, GRUJIC J. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J Antimicrob Chemother 2002; 50: 981-987.
29. ALVES CF, VITOR RW. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil. Parasite 2005; 12: 171-177.
30. DEROUIN F, ALMADANY R, CHAU F, ROUVEIX B, POCIDALO JJ. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother 1992; 36: 997-1001.
31. CHÊNE G, THIÉBAUT R. Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis. Mem Inst Oswaldo Cruz 2009; 104: 299-304.